Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
September 30, 2020 07:07 AM EDTUpdated October 1, 04:09 AM
Coronavirus

Covid-19 roundup: No­var­tis' Vas Narasimhan sees drugs as 'bridge' to vac­cines; Mod­er­na spot­lights el­der­ly re­spons­es in NE­JM

ENDPOINTS

No­var­tis may be stay­ing out of the vac­cine pack, but the Swiss phar­ma gi­ant in­sists that its drugs will still have a cru­cial role to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times